[go: up one dir, main page]

WO2007110003A3 - Micellar carriers for drugs with anti-cancer activity - Google Patents

Micellar carriers for drugs with anti-cancer activity Download PDF

Info

Publication number
WO2007110003A3
WO2007110003A3 PCT/CZ2007/000020 CZ2007000020W WO2007110003A3 WO 2007110003 A3 WO2007110003 A3 WO 2007110003A3 CZ 2007000020 W CZ2007000020 W CZ 2007000020W WO 2007110003 A3 WO2007110003 A3 WO 2007110003A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
cancer activity
micellar
micellar carriers
micelle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2007/000020
Other languages
French (fr)
Other versions
WO2007110003A2 (en
Inventor
Petr Chytil
Tomas Etrych
Martin Hruby
Karel Ulbrich
Blanka Rihova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2007110003A2 publication Critical patent/WO2007110003A2/en
Publication of WO2007110003A3 publication Critical patent/WO2007110003A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A micellar system destined for controlled release of medical drug is formed by a micellar structure, constituted by a hydrophilic or amphiphilic polymer, to which the drug is bound by a covalent linkage, the molecules of which are arranged on the hydrophilic surface of the micelle, while the nucleus of the micelle is constituted by hydrophobic components of the system, which are linked with the polymer on the surface by a chemical bond.
PCT/CZ2007/000020 2006-03-28 2007-03-28 Micellar carriers for drugs with anti-cancer activity Ceased WO2007110003A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20060207A CZ2006207A3 (en) 2006-03-28 2006-03-28 Medicament micellar carriers exhibiting antitumor activity
CZPV2006-207 2006-03-28

Publications (2)

Publication Number Publication Date
WO2007110003A2 WO2007110003A2 (en) 2007-10-04
WO2007110003A3 true WO2007110003A3 (en) 2008-05-15

Family

ID=38230079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2007/000020 Ceased WO2007110003A2 (en) 2006-03-28 2007-03-28 Micellar carriers for drugs with anti-cancer activity

Country Status (2)

Country Link
CZ (1) CZ2006207A3 (en)
WO (1) WO2007110003A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301288B6 (en) * 2008-10-23 2009-12-30 Zentiva, A. S Polymeric composition exhibiting synergistic activity when treating tumor diseases
CZ303072B6 (en) * 2009-02-13 2012-03-21 Zentiva, K.S. Paclitaxel and docetaxel polymeric conjugates with pH controlled release of cancerostatic
WO2010127271A1 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
EP2438908A1 (en) * 2010-10-11 2012-04-11 Vectum Pharma, S.L. Anchoring compositions for topical applications
FR2967581B1 (en) 2010-11-19 2012-12-28 Sanofi Aventis POLYMERIC CONJUGATES OF ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND POLYMERIC INTERMEDIATES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053473A2 (en) * 2001-12-20 2003-07-03 Zentiva, A.S. Ph-sensitive polymeric conjugates of an anthracycline drug

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053473A2 (en) * 2001-12-20 2003-07-03 Zentiva, A.S. Ph-sensitive polymeric conjugates of an anthracycline drug

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BADER ET AL: "Watersoluble Polymers in Medicine", DIE ANGEWANDTE MAKROMOLEKULARE CHEMIE, vol. 123/124, 1984, pages 457 - 485, XP002473699 *
BAE Y ET AL: "DESIGN OF ENVIRONMENT-SENSITIVE SUPRAMOLECULAR ASSEMBLIES FOR INTRACELLULAR DRUG DELIVERY: POLYMERIC MICELLES THAT ARE RESPONSIVE TO INTRACELLULAR PH CHANGE", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, WILEY VCH VERLAG, WEINHEIM, DE, vol. 42, no. 38, 6 October 2003 (2003-10-06), pages 4640 - 4643, XP001197447, ISSN: 1433-7851 *
CHYTIL ET AL: "Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: Effect of polymer chain modification", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 115, no. 1, 28 September 2006 (2006-09-28), pages 26 - 36, XP005663194, ISSN: 0168-3659 *
HRUBY M ET AL: "Polymeric micellar pH-sensitive drug delivery system for doxorubicin", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 103, no. 1, 2 March 2005 (2005-03-02), pages 137 - 148, XP004745763, ISSN: 0168-3659 *
KWON G S ET AL: "POLYMERIC MICELLES AS NEW DRUG CARRIERS", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 21, no. 2, 1996, pages 107 - 116, XP001152000, ISSN: 0169-409X *
LUKYANOV A N ET AL: "Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 56, no. 9, 7 May 2004 (2004-05-07), pages 1273 - 1289, XP002356816, ISSN: 0169-409X *
MASAYUKI YOKOYAMA ET AL: "POLYMER MICELLES AS NOVEL DRUG CARRIER: ADRIAMYCIN-CONJUGATED POLY(ETHYLENE GLYCOL)-POLY(ASPARTIC ACID) BLOCK COPOLYMER", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 1 - 3, January 1990 (1990-01-01), pages 269 - 278, XP000113384, ISSN: 0168-3659 *
NAKANISHI T ET AL: "Development of the polymer micelle carrier system for doxorubicin", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 1-3, 6 July 2001 (2001-07-06), pages 295 - 302, XP004297538, ISSN: 0168-3659 *
ORIENTI I ET AL: "Microspheres of poly(2-hydroxyethylmethacrylate-co-[beta]-methacryloy loxyethyldeoxycholate) cross-linked with ethylene glycol dimethacrylate", PHARMACEUTICA ACTA HELVETIAE 1995 NL, vol. 70, no. 3, 1995, pages 241 - 246, XP002473698, ISSN: 0031-6865 *
QIU L Y ET AL: "Polymer architecture and drug delivery", PHARMACEUTICAL RESEARCH 200601 US, vol. 23, no. 1, January 2006 (2006-01-01), pages 1 - 30, XP002473715, ISSN: 0724-8741 1573-904X *
TORCHILIN V P ET AL: "Amphiphilic poly-N-vinylpyrrolidones: - synthesis, properties and liposome surface modification", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 22, 15 November 2001 (2001-11-15), pages 3035 - 3044, XP004301382, ISSN: 0142-9612 *
UCHEGBU I F ET AL: "The lower critical solution temperature of doxorubicin polymer conjugates", PROCEEDINGS OF THE CONTROLLED RELEASE SOCIETY 1996 US, no. 23, 1996, pages 791 - 792, XP008089700, ISSN: 1022-0178 *
ULBRICH K ET AL: "POLYMERIC ANTICANCER DRUGS WITH PH-CONTROLLED ACTIVATION", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 56, no. 7, 2004, pages 1023 - 1050, XP008068789, ISSN: 0169-409X *
YOKOYAMA M: "BLOCK COPOLYMERS AS DRUG CARRIERS", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. 9, no. 3/4, 1992, pages 213 - 248, XP008054267, ISSN: 0743-4863 *
YOO H S ET AL: "Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 82, no. 1, 18 July 2002 (2002-07-18), pages 17 - 27, XP004369786, ISSN: 0168-3659 *
YOO HYUK SANG ET AL: "Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer", JOURNAL OF CONTROLLED RELEASE, vol. 70, no. 1-2, 29 January 2001 (2001-01-29), pages 63 - 70, XP002473697, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
WO2007110003A2 (en) 2007-10-04
CZ2006207A3 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
WO2007110003A3 (en) Micellar carriers for drugs with anti-cancer activity
WO2007103288A3 (en) Engineered antibody drug conjugates
Das et al. Stimuli-responsive boron-based materials in drug delivery
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
WO2007137170A3 (en) Anti-glypican-3 antibody drug conjugates
EP1981527A4 (en) THERMALLY TARGET DELIVERY OF DRUGS SUCH AS DOXORUBICIN
WO2008003329A3 (en) Nanoparticles for nucleic acid delivery
WO2005112886A3 (en) Methods and articles for the delivery of therapeutic agents
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
WO2009139939A3 (en) Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
CL2007003263A1 (en) COMPOUNDS DERIVED FROM 1,4-BENZOTIEPIN 1,1-DIOXIDE; PHARMACEUTICAL PRODUCT; PREPARATION PROCEDURE; AND USE FOR THE TREATMENT OF LIPID METABOLISM DISORDERS, HYPERLIPIDEMIA, INSULIN RESISTANCE, SNC DIABETES AND DISORDERS, E
DE602007011787D1 (en) MEMBRANE PROTEIN IMMOBILIZATION ON A CARRIER WITH AN AMPHIPHILEN MOLECULE
PT1834635E (en) Stable nanocapsule systems for the administration of active molecules
WO2007087256A3 (en) Method of preparing dendritic drugs
WO2009042064A3 (en) Oligomer-nucleoside phosphate conjugates
HK1208727A1 (en) Tumor cell separation/purification method and method of use thereof
BR112012015606A2 (en) "anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents"
AR088619A1 (en) METHOD FOR PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEXES
Jia et al. Bottlebrush polymer-conjugated melittin exhibits enhanced antitumor activity and better safety profile
EP2076247A4 (en) TUNABLE SELF-ADMINISTRATIVE DRUG DELIVERY SYSTEM
Rodríguez-Nogales et al. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine
EP2226083A4 (en) DRUG DELIVERY SYSTEM
WO2012097763A3 (en) A carrier for oromucosal, especially sublingual administration of physiologically active substances
WO2012018383A3 (en) Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07711112

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07711112

Country of ref document: EP

Kind code of ref document: A2